Further evidence in support of the role of TREG cells in suppressing anti-tumour immunity is the efficacy of anti-CTLA4 immunotherapy in the treatment of certain cancers (188) which primarily acts to restore effector T cell activation and function via the depletion of TREG cells expressing CTLA4+ (192, 193). The gene discussed is CTLA4; the disease is neoplasm.